Medical treatment of obesity: Modern approaches and prospects
https://doi.org/10.62751/2713-0177-2024-5-4-18
Abstract
Obesity is a chronic progressive disease that poses a major problem for modern healthcare due to the high and rapidly growing prevalence and development of severe complications such as cardiovascular diseases, type 2 diabetes mellitus, malignant neoplasms, etc. Effective treatment of obesity requires an integrated approach, where drug therapy and, in some cases, bariatric intervention complement lifestyle measures – nutrition correction and the use of regular physical activity. Successful treatment of obesity requires an individual approach to the patient, taking into account the initial body weight, the presence of risk factors or developed concomitant diseases, as well as the dynamics of weight loss during therapy. Drug therapy is an important part of the treatment of obese patients, because it allows you to achieve a more significant result of weight loss, and, importantly, to maintain a reduced weight. Drugs of the GLP-1 agonists, widely used today in the treatment of obesity, not only directly affect body weight, but also reduce the risks of severe cardiovascular diseases and metabolic disorders, thus leading to an improvement in the quality of life and an increase in its duration. The article presents the main approaches to the treatment of obese patients with a description of the modern possibilities of pharmacological treatment of obesity.
About the Authors
V. V. Titova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Victoria V. Titova – assistant at the Department of Endocrinology Medical Faculty
Moscow
F. O. Ushanova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Fatima O. Ushanova – Can. Sci. (Med.), Associate Professor of the Department of Endocrinology of the Faculty of Medicine
Moscow
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana Yu. Demidova – D. Sci. (Med.), Prof.
Moscow
References
1. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022; 1: 100004. doi:10.1016/j.obpill.2021.100004.
2. Здравоохранение в России. 2023: Стат.сб./Росстат. М.: З-46. 2023; 179 с. Доступ: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения – 01.11.2024).
3. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017; 6(2): 187–94. doi: 10.1007/s13679-017-0262-y.
4. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. с соавт. Ожирение. Клинические рекомендации. Consilium Medicum. 2021; 23(4): 311–325. doi: 10.26442/20751753.2021.4.200832.
5. Sherrington A, Newham JJ, Bell R et al. Systematic review and meta-analysis of internet-delivered interventions providing personalized feedback for weight loss in overweight and obese adults. Obes Rev. 2016; 17(6): 541–51. doi: 10.1111/obr.12396.
6. Wadden TA, Neiberg RH, Wing RR et al.; Look AHEAD Research Group. Four-year weight losses in the Look AHEAD study: Factors associated with long-term success. Obesity (Silver Spring). 2011; 19(10): 1987–98. doi:10.1038/oby.2011.230.
7. Karam G, Agarwal A, Sadeghirad B et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ. 2023; 380: e072003. doi: 10.1136/bmj-2022-072003.
8. Dinu M, Pagliai G, Angelino D et al. Effects of popular diets on anthropometric and cardiometabolic parameters: An umbrella review of meta-analyses of randomized controlled trials. Adv Nutr. 2020; 11(4): 815–33. doi: 10.1093/advances/nmaa006.
9. Piercy KL, Troiano RP, Ballard RM et al. The physical activity guidelines for Americans. JAMA. 2018; 320(19): 2020–28. doi: 10.1001/jama.2018.14854.
10. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1): 155–61. doi: 10.2337/diacare.27.1.155.
11. Демидова Т.Ю., Измайлова М.Я., Ушакова С.Е. с соавт. Оценка эффективности снижения веса и безопасности применения сибутраминсодержащих лекарственных препаратов у пациентов с алиментарным ожирением. Фармация и фармакология. 2022; 10(3): 289–304. doi: 10.19163/2307-9266-2022-10-3-289-304.
12. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27(12): 1437–46. doi: 10.1038/sj.ijo.0802475.
13. James WPT, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet. 2000; 356(9248): 2119–25. doi: 10.1016/s0140-6736(00)03491-7.
14. Инструкции по медицинскому применению лекарственных препаратов с МНН лираглутид. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/GRLS.aspx-?RegNumber=&MnnR=лираглутид&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0®type=12c6&pageSize=10&token=4cc2b604-5e85-4461-908d-c32ad2a79ed1&order=Registered&orderType=-desc&pageNum=1 (дата обращения – 01.11.2024).
15. Marso SP, Bain SC, Consoli A et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. doi: 10.1056/NEJMoa1607141.
16. Wadden TA, Tronieri JS, Sugimoto D et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020; 28(3): 529–36. doi: 10.1002/oby.22726.
17. Pi-Sunyer X, Astrup A, Fujioka K et al.; SCALE Obesity and Prediabetes NN8022- 1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373(1): 11–22. doi: 10.1056/NEJMoa1411892.
18. Аметов А.С., Шохин И.Е., Рогожина Е.А. с соавт. Российская разработка для лекарственной независимости в эндокринологии: сравнительный анализ биоэквивалентности, безопасности и переносимости первого отечественного лираглутида. Фармация и фармакология. 2023; 11(3): 255–276. doi: 10.19163/2307-9266-2023-11-3-255-276.
19. Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41(2): 258–66. doi: 10.2337/dc17-0417.
20. Thethi TK, Pratley R, Efficacy MJJ. Safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020; 22(8): 1263–77. doi: 10.1111/dom.14054.
21. Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989–1002. doi: 10.1056/NEJMoa2032183.
22. Davies M, Faerch L, Jeppesen OK et al.; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971–84. doi: 10.1016/S0140-6736(21)00213-0.
23. Wadden TA, Bailey TS, Billings LK et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021; 325(14): 1403–13. doi: 10.1001/jama.2021.1831.
24. Rubino D, Abrahamsson N, Davies M et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414–25. doi: 10.1001/jama.2021.3224.
25. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022; 28(10): 2083–91. doi: 10.1038/s41591-022-02026-4.
26. Rubino DM, Greenway FL, Khalid U et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022; 327(2): 138–50. doi: 10.1001/jama.2021.23619.
27. Deanfield J, Verma S, Scirica BM et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454): 773–86. doi: 10.1016/S0140-6736(24)01498-3.
28. Kosiborod MN, Abildstrøm SZ, Borlaug BA et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–84. doi: 10.1056/NEJMoa2306963.
29. Zhang R, Hou QC, Li BH et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: A subgroup meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023; 14: 1132004. doi: 10.3389/fendo.2023.1132004.
30. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/ (дата обращения – 01.11.2024).
31. Jastreboff AM, Aronne LJ, Ahmad NN et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–16. doi: 10.1056/NEJMoa2206038.
32. Lean MEJ, Leslie WS, Barnes AC et al. Durability of a primary careled weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019; 7(5): 344–55. doi: 10.1016/S2213-8587(19)30068-3.
Review
For citations:
Titova V.V., Ushanova F.O., Demidova T.Yu. Medical treatment of obesity: Modern approaches and prospects. FOCUS. Endocrinology. 2024;5(4):40-48. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-4-18
Views:
160
Email this article 